AstraZeneca, Isis unite to develop antisense cancer drugs

12/12/2012 | Reuters · Genetic Engineering & Biotechnology News

Isis Pharmaceuticals and AstraZeneca agreed to jointly discover and develop antisense treatments against five cancer targets. The agreement also covers rights to develop and market Isis' experimental drug ISIS-STAT3Rx, which is in Phase I development for patients with advanced lymphomas. The deal entitles Isis to $31 million upfront and near-term fees, plus potential licensing and milestone payments and sales royalties.

View Full Article in:

Reuters · Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care